Market Closed -
Nasdaq
21:00:00 26/06/2024 BST
|
5-day change
|
1st Jan Change
|
2.47
USD
|
-4.26%
|
|
-6.44%
|
-26.49%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
678.2
|
425.7
|
455.5
|
321.3
|
239.5
|
-
|
-
|
Enterprise Value (EV)
1 |
678.2
|
425.7
|
455.5
|
321.3
|
239.5
|
239.5
|
239.5
|
P/E ratio
|
-3.04
x
|
-3.39
x
|
-5.96
x
|
-2.45
x
|
-1.72
x
|
-1.38
x
|
-1.56
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
13.6
x
|
3.49
x
|
4.97
x
|
3.22
x
|
8.33
x
|
13
x
|
EV / Revenue
|
-
|
13.6
x
|
3.49
x
|
4.97
x
|
3.22
x
|
8.33
x
|
13
x
|
EV / EBITDA
|
-5,470,709
x
|
-3,110,265
x
|
-8,316,569
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-5.21
x
|
-4.05
x
|
-14.8
x
|
-3.37
x
|
-2.75
x
|
-1.92
x
|
-1.43
x
|
FCF Yield
|
-19.2%
|
-24.7%
|
-6.74%
|
-29.6%
|
-36.3%
|
-52.2%
|
-70.2%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
61,820
|
62,506
|
85,949
|
95,624
|
96,958
|
-
|
-
|
Reference price
2 |
10.97
|
6.810
|
5.300
|
3.360
|
2.470
|
2.470
|
2.470
|
Announcement Date
|
11/03/21
|
10/03/22
|
09/03/23
|
07/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
31.24
|
130.5
|
64.7
|
74.39
|
28.75
|
18.37
|
EBITDA
|
-
|
-124
|
-136.9
|
-54.77
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-126.5
|
-141.4
|
-59.95
|
-129.5
|
-149
|
-217.9
|
-213.6
|
Operating Margin
|
-
|
-
|
-452.69%
|
-45.94%
|
-200.15%
|
-200.24%
|
-757.86%
|
-1,162.92%
|
Earnings before Tax (EBT)
1 |
-
|
-129.8
|
-125
|
-63.46
|
-123.3
|
-152.4
|
-226.5
|
-218.4
|
Net income
1 |
-
|
-129.8
|
-125
|
-64
|
-123.4
|
-152.4
|
-226.5
|
-218.4
|
Net margin
|
-
|
-
|
-400.07%
|
-49.05%
|
-190.76%
|
-204.82%
|
-787.76%
|
-1,188.92%
|
EPS
2 |
-5.500
|
-3.610
|
-2.010
|
-0.8900
|
-1.370
|
-1.440
|
-1.796
|
-1.583
|
Free Cash Flow
1 |
-
|
-130.2
|
-105.2
|
-30.7
|
-95.23
|
-87
|
-125
|
-168
|
FCF margin
|
-
|
-
|
-336.7%
|
-23.52%
|
-147.18%
|
-116.95%
|
-434.78%
|
-914.7%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/06/20
|
11/03/21
|
10/03/22
|
09/03/23
|
07/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
31.24
|
1.435
|
2.7
|
116.3
|
10.05
|
10.34
|
20.01
|
9.352
|
25
|
28.14
|
15.42
|
15.42
|
15.42
|
11.25
|
3.75
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-17.48
|
-56.96
|
-41.54
|
71.78
|
-33.22
|
-39.52
|
-27.86
|
-36.22
|
-25.91
|
-24.58
|
-39.46
|
-40.72
|
-44.21
|
-49.5
|
-60
|
Operating Margin
|
-55.95%
|
-3,969.41%
|
-1,538.7%
|
61.72%
|
-330.52%
|
-382.06%
|
-139.18%
|
-387.32%
|
-103.66%
|
-87.33%
|
-255.95%
|
-264.14%
|
-286.74%
|
-440%
|
-1,600%
|
Earnings before Tax (EBT)
1 |
1.469
|
-58.06
|
-43.04
|
70.66
|
-33.03
|
-38.85
|
-27.46
|
-31.67
|
-25.35
|
-24.27
|
-40.66
|
-41.96
|
-45.47
|
-52.15
|
-62.4
|
Net income
1 |
1.469
|
-58.06
|
-43.04
|
70.41
|
-33.32
|
-38.85
|
-27.46
|
-31.78
|
-25.35
|
-24.27
|
-40.66
|
-41.96
|
-45.47
|
-52.15
|
-62.4
|
Net margin
|
4.7%
|
-4,045.78%
|
-1,593.93%
|
60.54%
|
-331.49%
|
-375.59%
|
-137.19%
|
-339.8%
|
-101.42%
|
-86.26%
|
-263.74%
|
-272.15%
|
-294.97%
|
-463.56%
|
-1,664%
|
EPS
2 |
0.0200
|
-0.9300
|
-0.6900
|
0.9200
|
-0.3900
|
-0.4500
|
-0.3200
|
-0.3500
|
-0.2700
|
-0.2500
|
-0.4180
|
-0.4060
|
-0.4100
|
-0.4567
|
-0.5467
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/03/22
|
12/05/22
|
11/08/22
|
10/11/22
|
09/03/23
|
09/05/23
|
08/08/23
|
09/11/23
|
07/03/24
|
14/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-130
|
-105
|
-30.7
|
-95.2
|
-87
|
-125
|
-168
|
ROE (net income / shareholders' equity)
|
-
|
-231%
|
-59.8%
|
-37.2%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-3.150
|
-1.650
|
-0.3700
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
16.9
|
2.63
|
3.92
|
3.07
|
0.52
|
4.05
|
4.4
|
Capex / Sales
|
-
|
-
|
8.43%
|
3.01%
|
4.74%
|
0.7%
|
14.09%
|
23.96%
|
Announcement Date
|
19/06/20
|
11/03/21
|
10/03/22
|
09/03/23
|
07/03/24
|
-
|
-
|
-
|
Last Close Price
2.47
USD Average target price
14
USD Spread / Average Target +466.80% Consensus |
1st Jan change
|
Capi.
|
---|
| -26.49% | 250M | | +16.49% | 122B | | +21.73% | 116B | | +22.18% | 27.03B | | -21.81% | 20.36B | | -16.89% | 16.43B | | -18.81% | 15.91B | | -44.74% | 15.6B | | +62.72% | 14.94B | | +3.09% | 13.59B |
Bio Therapeutic Drugs
|